文献速递心境障碍

抗抑郁药治疗无效的难治性抑郁症:比较增效与换药效果的随机临床试验

Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial.
PubMed 文献 · Mol Psychiatry · 2024-03-07

本研究为多中心、8周、随机、开放标签试验,纳入278例难治性抑郁症患者,按1:1:1分配至阿立哌唑增效、重复经颅磁刺激增效或换用文拉法辛XR(或不适合者用度洛西汀)。主要指标MADRS上,rTMS增效优于换药(p=0.015),阿立哌唑增效未优于换药(p=0.069)。

要点

  • rTMS增效在MADRS上优于换药(评分变化-17.39 vs -13.22,p=0.015)。
  • 阿立哌唑增效在MADRS上未显著优于换药(-14.9 vs -13.22,p=0.069)。
  • 在抑郁症状问卷上阿立哌唑增效优于换药(p=0.003),rTMS未优于换药(p=0.031)。

核心结论

  • 在难治性抑郁症中,rTMS增效在主要指标MADRS上比换用抗抑郁药更有效。
  • 阿立哌唑增效在MADRS上未显著优于换药,但在抑郁症状问卷上优于换药。

研究设计与样本

  • 多中心、8周、随机、开放标签试验,278例难治性抑郁症患者按1:1:1分配至阿立哌唑增效、rTMS增效或换用文拉法辛XR(或不适合者用度洛西汀)。
  • 235例完成研究,260例至少有一次基线后MADRS评估者纳入分析;平均年龄45.6岁(SD 15.3),女性196例、男性82例。

主要发现

  • MADRS评分变化(标准误):rTMS增效-17.39(1.3),阿立哌唑增效-14.9(1.1),换药-13.22(1.1)。
  • rTMS增效 vs 换药在MADRS上p=0.015;阿立哌唑增效 vs 换药在MADRS上p=0.069。
  • 抑郁症状问卷平均变化(标准误):阿立哌唑增效-37.79(2.9),rTMS增效-42.96(3.6),换药-34.45(3.0)。
  • 阿立哌唑增效 vs 换药在抑郁症状问卷上p=0.003;rTMS增效 vs 换药在抑郁症状问卷上p=0.031。

临床怎么用

  • 基于主要指标结果,临床医生应考虑对难治性抑郁症早期使用rTMS增效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Further research is needed to help improve both the standard of care and the outcome for patients with treatment-resistant depression. A particularly critical evidence gap exists with respect to whether pharmacological or non-pharmacological augmentation is superior to antidepressant switch, or vice-versa. The objective of this study was to compare the effectiveness of augmentation with aripiprazole or repetitive transcranial magnetic stimulation versus switching to the antidepressant venlafaxine XR (or duloxetine for those not eligible to receive venlafaxine) for treatment-resistant depression. In this multi-site, 8-week, randomized, open-label study, 278 subjects (196 females and 82 males, mean age 45.6 years (SD 15.3)) with treatment-resistant depression were assigned in a 1:1:1 fashion to treatment with either of these three interventions; 235 subjects completed the study. 260 randomized subjects with at least one post-baseline Montgomery-Asberg Depression Rating (MADRS) assessment were included in the analysis. Repetitive transcranial magnetic stimulation (score change (standard error (se)) = -17.39 (1.3) (p = 0.015) but not aripiprazole augmentation (score change (se) = -14.9 (1.1) (p = 0.069) was superior to switch (score change (se) = -13.22 (1.1)) on the MADRS. Aripiprazole (mean change (se) = -37.79 (2.9) (p = 0.003) but not repetitive transcranial magnetic stimulation augmentation (mean change (se) = -42.96 (3.6) (p = 0.031) was superior to switch (mean change (se) = -34.45 (3.0)) on the symptoms of depression questionnaire. Repetitive transcranial magnetic stimulation augmentation was shown to be more effective than switching antidepressants in treatment-resistant depression on the study primary measure. In light of these findings, clinicians should consider repetitive transcranial magnetic stimulation augmentation early-on for treatment-resistant depression.Trial registration: ClinicalTrials.gov, NCT02977299.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Papakostas GI, Trivedi MH, Shelton RC, et al. Comparative effectiveness research trial for antidepressant incomplete and non-responders with treatment resistant depression (ASCERTAIN-TRD) a randomized clinical trial. Mol Psychiatry. 2024. PMID: 38454079. doi:10.1038/s41380-024-02468-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。